If you have been reading about metabolic modulator and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
== External links == Clinical trial number NCT03422653 for "A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)" at ClinicalTrials.gov Clinical trial number NCT03636269 for "CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-2)" at ClinicalTrials.gov
== External links == "Opioid Receptors: μ". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. mu+Opioid+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human OPRM1 genome location and OPRM1 gene details page in the UCSC Genome Browser.
=== 16 March === Poland announced that it will provide four MiG-29s to Ukraine with in the next few days. The rest of Poland's MiG-29 fleet is being serviced to also be ready for transfer at a later time. The total number to be sent is unclear with different sources speculating from 11 to 19.
Tumor biopsy samples used for diagnostics always contain as little as 5% of the target variant as compared to wildtype sequence. Also, for noninvasive applications from peripheral blood or urine, the DNA test must be specific enough to detect mutations at variant allele frequencies of less than 0.1%. Currently, by optimizing the traditional PCR, there's a new invention, amplification-refractory mutation system (ARMS) is a method for detecting DNA sequence variants in cancer. The principle behind ARMS is that the enzymatic extension activity of DNA polymerases is highly sensitive to mismatches near the 3' end of primer. Many different companies have developed diagnostics tests based on ARMS PCR primers. For instance, Qiagen therascreen, Roche cobas and Biomerieux THxID have developed FDA approved PCR tests for detecting lung, colon cancer and metastatic melanoma mutations in the KRAS, EGFR and BRAF genes. Their IVD kits were basically validated on genomic DNA extracted from FFPE tissue. There are also microarrays that utilize hybridization mechanism to diagnose cancer. More than a million of different probes can be synthesized on an array with Affymetrix's Genechip technology with a detection limit of one to ten copies of mRNA per well. Optimized microarrays are typically considered to produce repeatable relative quantitation of different targets.
Sources: en.wikipedia.org
Fibrillogenesis is the development of fine fibrils normally present in collagen fibers of connective tissue. It is derived from the New Latin fibrilla (meaning fibrils, or pertaining to fibrils) and Greek genesis (to create, the process by which something is created). The assembly of collagen fibrils, fibrillogenesis appears to be a self-assembly process although there is much speculation about the specifics of the mechanism through which the body produces collagen fibrils. In the body, collagen fibrils are composed of several types of collagen as well as macromolecules. Type I collagen is the most abundant structural macromolecule within the vertebrate body and also represents the most abundant collagen found within various collagen fibrils There are immense differences in the types of collagen fibrils that exist within the body. For instance, fibrils within the tendon vary in width and are banded into aggregates that form fibril bundles that resist forces of tension within one dimension. Similarly, fibrils that form the translucent corneal stromal matrix form orthogonal sheets and withstand the force of traction in two dimensions. These two structurally different collagen fibrils are speculated to be formed from the same molecules with type I collagen being the primary collagen found within both structures.
The first reference to Israel in non-biblical sources is found in the Merneptah Stele in c. 1209 BCE. The inscription is very brief and says: "Israel is laid waste and his seed is not". The inscription refers to a people, not an individual or nation state, who inhabit central Palestine or the highlands of Samaria. Some Egyptologists suggest that Israel appeared in earlier topographical reliefs, dating to the Eighteenth Dynasty or Nineteenth Dynasty (i.e. reign of Ramesses II) , but this reading remains controversial. In the Hebrew Bible, Israel first appears in Genesis 32:29, where an angel renames Jacob to Israel after Jacob fought with him. According to the folk etymology given in the text, Israel is derived from yisra, "to prevail over" or "to struggle with", and El, a Canaanite-Mesopotamian creator god that is tenuously identified with Yahweh. However, modern scholarship interprets El as the subject, "El rules/struggles", from sarar (שָׂרַר) 'to rule' (cognate with sar (שַׂר) 'ruler', Akkadian šarru 'ruler, king'), which is likely cognate with the similar root sara (שׂרה) "fought, strove, contended". Dr. Tzemah Yoreh clarifies that Israel is a combination of 'to strive with' (ש.ר.ה) and 'God' (אל) and that Jacob's name alternates between Jacob and Israel in the biblical narrative, even after his renaming, due to the authors having different opinions about Jacob's moral character. The gradual ethnonymic shift from "Israelites" to "Jews", regardless of their descent from Judah is made explicit in the Book of Esther (4th century BCE) of the Tanakh.
==== Ban ==== Banban Akaza (赤座 伴番, Akaza Banban), also known as "Ban" (バン), is a hot-headed, chaotic, loudmouthed, bad-tempered, yet fiercely loyal and friendly rookie member of the S.P.D., who previously trained in space before being assigned to lead S.P.D.'s Earth unit in the field as Deka Red (デカレッド, Deka Reddo). While he joins the newly created Fire Squad as an elite officer in the series finale, he occasionally returns to help his original team. Initially having an immature personality, he slowly matures throughout the series. In battle, Ban is a practitioner of the space martial art Juu Kune Do (ジュウクンドー, Jū Kun Dō), which blends unarmed martial arts skills with gunplay. As Deka Red, he dual wields a pair of D-Magnum (ディーマグナム, Dī Magunamu) rayguns, which can combine to form the Hybrid Magnum (ハイブリッドマグナム, Haiburiddo Magunamu) shotgun and allow him to perform the Magnum Execution (マグナムエクスキュージョン, Magunamu Ekusukyūjon), Moonsault Shot (ムーンサルトショット, Mūnsaruto Shotto), Endless Shot (エンドレスショット, Endoresu Shotto), Hurricane Shot (ハリケーンショット, Harikēn Shotto), and Moonsault Galaxy Shot (ムーンサルトギャラクシーショット, Mūnsaruto Gyarakushī Shotto) attacks. He also shares riding the Machine Doberman (マシンドーベルマン, Mashin Dōberuman) police car with Jasmine. If necessary, he can borrow Doggie Kruger's D-Sword Vega to perform the Akaza Sword Art: Raijin Sword (赤座剣法・雷神剣, Akaza Kenpō Raijin Ken) and Impulse Vega Slash (インパルスベガスラッシュ, Inparusu Bega Surasshu) attacks. During the events of the crossover film Mahō Sentai Magiranger vs.
The ascent led through forests of chestnut, laurels, and heaths, and onto higher, barren volcanic plains such as Llano del Retama, where vegetation diminished and only shrubs and wildlife remained. At Estancia de los Ingleses, a traditional rest point at about 8,000 feet (2,400 m), the group endured a cold, windy night before continuing the climb at 3 a.m. on 22 June 1799. They crossed the Malpays, an area of broken lava and little vegetation, and reached the summit at 8 a.m. At the peak, the party observed the structure of the volcano, measured ground temperatures, and collected air samples. The elliptical crater showed no recent eruptions inside, but the volcano remained active, with recent lava flows and geothermal activity. The summit provided panoramic views of the surrounding islands and the diverse ecological zones descending from the peak, which Humboldt recorded in a sketch. He noted five distinct vegetation zones, from grasses at the summit to cultivated tropical and temperate plants near the coast. The descent took the party back through the varying ecological regions. Humboldt made broader geological observations, considering questions about the structure and origins of volcanoes and the laws governing geological phenomena. The round trip from La Orotava to the summit and back lasted twenty-one hours. The Pizarro’s departure was delayed until 24 or 25 June 1799 due to the presence of an English squadron, allowing Humboldt and Bonpland additional time to explore the island’s surroundings.
=== Cell signalling === Citicoline may enhance cellular communication by increasing levels of neurotransmitters. The choline component of citicoline is used to create acetylcholine, which is a neurotransmitter in the human brain. Clinical trials have found that citicoline supplementation might improve focus and attention.
Sources: en.wikipedia.org
=== Cancer === Current clinical trials testing synthetic platelets offer a promising strategy for oncology applications by facilitating targeted drug delivery to tumors and reducing off-target toxicity in cancer therapy. Natural platelets were reported to interact with cancer cells through mechanisms such as immune evasion, angiogenesis, and metastasis. Specific to oncology, synthetic platelets are applied using targeted drug delivery. Platelet-mimicking nanoparticles developed from self-assembling peptides were found to adhere to tumor endothelial cells and induce localized coagulation, forming artificial clots that disrupt tumor vasculature. This approach reduces blood supply to the tumor, effectively starving cancer cells while preventing metastatic spread. Furthermore, synthetic platelets designed to deliver chemotherapy drugs can leverage natural platelet-tumor interactions to deliver drugs directly to cancerous cells, which has been seen to reduce off-target effects and improve therapeutic outcomes. Immunotherapy and radiation sensitization are additional application areas of platelet-mimicking particles. Platelet-inspired nanomedicine uses extracellular vesicles and platelet-derived biomaterials to enhance immune responses against tumors. These biomimetic platforms can be designed to carry immune checkpoint inhibitors and pro-inflammatory cytokines, which can help overcome immune evasion mechanisms employed by cancer cells.
Side effects are generally similar to other antipsychotics. The drug has a relatively well tolerated side effect profile, with low propensity for QTc interval changes, weight gain and lipid-related adverse effects. In a 2013 meta-analysis of the efficacy and tolerability of 15 antipsychotic drugs, it was found to produce the second least (after haloperidol) weight gain, the least QT interval prolongation, the fourth most extrapyramidal side effects (after haloperidol, zotepine and chlorpromazine), and the sixth least sedation (after paliperidone, sertindole, amisulpride, iloperidone and aripiprazole). As with other atypical neuroleptics, lurasidone should be used with caution in the elderly because it puts them at an increased risk for a stroke or transient ischemic attack; however, these risks are not likely to be greater than those associated with antipsychotics of other classes. Similarly, lurasidone should not be used to treat dementia-related psychosis, as evidence has shown increased mortality with antipsychotic use. Weight gain is reported in up to 15 and 16 percent of users. Other possible side effects include vomiting, akathisia, dystonia, parkinsonism, somnolence, dizziness, sedation and nausea.
There are different short-term and long-term effects that can arise from mutations. Smaller ones would be a halting of the cell cycle at numerous points. This means that a codon coding for the amino acid glycine may be changed to a stop codon, causing the proteins that should have been produced to be deformed and unable to complete their intended tasks. Because the mutations can affect the DNA and thus the chromatin, it can prohibit mitosis from occurring due to the lack of a complete chromosome. Problems can also arise during the processes of transcription and replication of DNA. These all prohibit the cell from reproduction and thus lead to the death of the cell. Long-term effects can be a permanent changing of a chromosome, which can lead to a mutation. These mutations can be either beneficial or detrimental. Cancer is an example of how they can be detrimental. Other effects of point mutations, or single nucleotide polymorphisms in DNA, depend on the location of the mutation within the gene. For example, if the mutation occurs in the region of the gene responsible for coding, the amino acid sequence of the encoded protein may be altered, causing a change in the function, protein localization, stability of the protein or protein complex. Many methods have been proposed to predict the effects of missense mutations on proteins.
== Examples == Water, air, alcohol, glycerol, and thin motor oil are all examples of Newtonian fluids over the range of shear stresses and shear rates encountered in everyday life. Single-phase fluids made up of small molecules are generally (although not exclusively) Newtonian.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.